Bladder Cancer Market to Witness Moderate Growth by 2017, Despite Anticipate?d Launch of EOquin

The bladder cancer therapeutics market in the six major countries (6MM) — the US, France, Germany, Italy, Spain and UK — is forecast to climb from $239.3 million in 2012 to $297.5 million by 2017, at a Compound Annual Growth Rate (CAGR) of 4.5%, says a new report from research and consulting firm GlobalData.

According to the company’s latest report*, the US market will continue to generate the majority of sales, with its revenue increasing from $139.4 million in 2012 to $181.1 million by 2017, at a CAGR of 5.4%. This is due to the presence of higher-priced drugs in the US market, as opposed to other countries.

Shabaaz Ali, GlobalData’s Analyst covering Oncology and Hematology, says: “The major drivers of the bladder cancer market are the increasing numbers of incident cases across the 6MM and the expected launch of Spectrum Pharmaceuticals’ EOquin. This therapy is the only product in the pipeline that will enter the market during the forecast period.”

GlobalData expects the worldwide sales of EOquin to reach $13.2 million in 2016, before almost doubling to $26.1 million by 2017, accounting for 8.8% of sales in that year.

However, the lack of late-stage, company-sponsored developments in the bladder cancer setting by large pharmaceutical organizations will result in fewer pipeline products entering the market, subsequently restricting further growth.

“Considering the commercial viability of this market, it is strange to find so few companies involved in drug development. As this setting continues to remain greatly unsaturated, there is plentiful room for new entrants to pitch their successful therapies,” Ali concludes.

*OpportunityAnalyzer: Bladder Cancer – Opportunity Analysis and Forecasts to 2017